佐力药业2月3日获融资买入1873.84万元，融资余额6.01亿元

Core Viewpoint - Zhaoli Pharmaceutical has shown a mixed performance in financing activities and stockholder dynamics, with significant revenue growth and profit increase reported for the year 2025. Financing Activities - On February 3, Zhaoli Pharmaceutical's financing buy-in amounted to 18.73 million yuan, while financing repayment was 19.85 million yuan, resulting in a net financing outflow of 1.11 million yuan [1] - As of February 3, the total financing and securities balance for Zhaoli Pharmaceutical was 604 million yuan, with the financing balance accounting for 5.03% of the circulating market value, indicating a high level compared to the past year [1] - The company had a securities lending balance of 2.75 million yuan, with a lending volume of 162,000 shares, also reflecting a high level compared to the past year [1] Company Performance - For the period from January to September 2025, Zhaoli Pharmaceutical achieved an operating income of 2.28 billion yuan, representing a year-on-year growth of 11.48% [2] - The net profit attributable to the parent company for the same period was 510 million yuan, showing a year-on-year increase of 21.00% [2] Shareholder Dynamics - As of September 30, 2025, the number of shareholders for Zhaoli Pharmaceutical reached 41,400, an increase of 7.31% compared to the previous period [2] - The average circulating shares per person decreased by 6.82% to 14,562 shares [2] - The company has distributed a total of 1.442 billion yuan in dividends since its A-share listing, with 942 million yuan distributed in the last three years [3]